All In Biotech

Drugs by condition

Drugs approved for hemophilia

Brand-name prescription drugs and biologics whose FDA label lists hemophilia as an approved use. Matched on the label phrases: "hemophilia".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

7

Still marketed, NDA or BLA

Drug classes

4

Novel drugs

4

New molecular entities and new biologics

In development

19

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for hemophilia.

  • Qfitlia (Fitusiran Sodium) · Genzyme Corp NovelOrphanMar 28, 2025
  • Alhemo (Concizumab-Mtci) · Novo Nordisk INC NovelPriority reviewOrphanDec 20, 2024
  • Hympavzi (Marstacimab-Hncq) · Pfizer INC NovelOrphanOct 11, 2024
  • Tranexamic Acid (Tranexamic Acid) · Exela Pharma Apr 15, 2019
  • Hemlibra (Emicizumab) · Genentech INC NovelBreakthrough therapyPriority reviewOrphanNov 16, 2017

All approved drugs for hemophilia, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 26 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Antifibrinolytic Agent (2)

Antithrombin-directed RNA Interaction (1)

  • Qfitlia Fitusiran Sodium · Genzyme Corp · 2025

Tissue Factor Pathway Inhibitor Antagonist (1)

  • Alhemo Concizumab-Mtci · Novo Nordisk INC · 2024

Class not listed in FDA's data (3)

  • Hympavzi Marstacimab-Hncq · Pfizer INC · 2024
  • Hemlibra Emicizumab · Genentech INC · 2017
  • Ddavp Desmopressin Acetate · J Molner · 1984

Drugs in development for hemophilia

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • KN057Phase 34 trials

    Suzhou Alphamab Co., Ltd. · Hemophilia A Without Inhibitor, Hemophilia B Without Inhibitor, Hemophilia a and B

  • SR604Phase 34 trials

    Shanghai RAAS Blood Products Co., Ltd. · Factor VII Deficiency, Hemophilia A, Hemophilia B

  • BIVV001efanesoctocog, AltuvoctPhase 33 trials

    Swedish Orphan Biovitrum · Haemophilia A (Moderate or Severe), Hemophilia A, Hemophilia A, Severe

  • bypassing agentsClotting factor concentrates, CFCPhase 33 trials

    Sanofi · Hemophilia, Von Willebrand Disease, Type 3

  • FRSW107Phase 33 trials

    Hangzhou Gensciences Biopharmaceutical Co., Ltd. · Severe Hemophilia A

  • GS1191-0445Phase 32 trials

    Gritgen Therapeutics Co., Ltd. · Severe Hemophilia A, Hemophilia A

  • NXT007Zemocimig, RO7589655Phase 32 trials

    Roche (Genentech) · Hemophilia A

  • Valoctocogene roxaparvovecBMN 270, GENEr8Phase 32 trials

    BioMarin · Hemophilia A, Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII

  • FRSW117Recombinant human coagulation factor Ⅷ-Fc fusion proteinPhase 31 trial

    Hangzhou Gensciences Biopharmaceutical Co., Ltd. · Severe Hemophilia A

  • PF-06838435fidanacogene elaparvovecPhase 31 trial

    Pfizer · Hemophilia B

  • SKP-0141Phase 31 trial

    SK Plasma Co., Ltd. · Hemophilia A, Severe

  • STSP-0601Phase 31 trial

    Jiangsu BioJeTay Biotechnology Co., Ltd. · Hemophilia

  • ARD001Phase 21 trial

    Arditus Pte Ltd · Hemophilia A, Healthy Adult Participants

  • ASC618Phase 21 trial

    ASC Therapeutics · Hemophilia A

  • AskBio009BAX 335Phase 21 trial

    Takeda · Hemophilia B

  • BAY2599023DTX201Phase 21 trial

    Bayer · Hemophilia A

  • LNP1265Phase 21 trial

    Regeneron · Hemophilia B

  • REGV131Phase 21 trial

    Regeneron · Hemophilia B

  • SPK-8011QQRO7878488Phase 21 trial

    Roche (Genentech) · Hemophilia A

1 discontinued brand-name drugs whose label still names it

More on hemophilia: recruiting trials · published research

Related in hematology and blood cancers: Multiple myeloma · Acute myeloid leukemia · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Chronic myeloid leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Myelodysplastic syndromes · Myelofibrosis · Sickle cell disease

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.